<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444651</url>
  </required_header>
  <id_info>
    <org_study_id>2010P-001519</org_study_id>
    <nct_id>NCT01444651</nct_id>
  </id_info>
  <brief_title>A Trial of Tadalafil and Glycemic Traits</brief_title>
  <official_title>Phase 3 Randomized Trial of Tadalafil and Glycemic Traits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas J. Wang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if tadalafil can help overweight and obese people
      metabolize blood sugar more efficiently. The investigators also want to find out if 20 mg/day
      of tadalafil for 3 months is safe to take without causing too many side effects. The
      investigators are plan to enroll 100 subjects at Massachusetts General Hospital (MGH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is examining changes in insulin resistance and glucose tolerance following 3
      months of treatment with oral, once daily tadalafil.

      The investigators primary hypotheses are that measurable decreases in insulin resistance (as
      measured by HOMA-IR) and increases in insulin sensitivity (as measured by the Matsuda index)
      will occur following 3 months of treatment with oral tadalafil 20 mg daily compared to
      placebo.

      The investigators secondary hypotheses are that improvements in average glycemia (as measured
      by hemoglobin A1C), pancreatic beta cell function (as measured by the oral disposition
      index), and body composition (including weight, waist circumference, body mass index, and
      waist-hip ratio) will occur as a result of tadalafil-mediated changes in the cGMP pathway.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The primary endpoint is defined as the treatment group difference in the change in insulin resistance (baseline HOMA-IR minus 3-month HOMA-IR). HOMA-IR = [fasting glucose * fasting insulin]/405</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline to 3-month Change in Insulin Sensitivity, as Measured by the Matsuda Index</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The secondary endpoint is defined as the treatment group difference in the change in Matsuda Index (baseline minus 3-month). This index is a measure of insulin resistance derived from a frequently sampled oral glucose tolerance test, obtaining glucose and insulin levels in the fasting state, as well as 30, 60, 90, and 120 min after administration of oral glucose load. Matsuda index = 10,000/SQRT [fasting glucose*fasting insulin* (mean glucose from time 30, 60, 90, 120 min) * (mean insulin at time 30, 60, 90, and 120 min)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to 3-month Change in Endothelial Function Measured by EndoPAT</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Endothelial function was measured using the reactive hyperemia index, acquired using EndoPAT device. Peripheral arterial tonometry probes were placed on both index fingers. After a 5 min equilibration period, a blood pressure cuff was inflated to 200 mmHg and kept inflated for 5 min. The cuff was then rapidly deflated and the reactive hyperemic response pulse volume recorded, where RHI = ratio of hyperemic finger pulse volume (post-cuff inflation / pre-cuff inflation) to control finger pulse volume (post-cuff inflation / pre-cuff inflation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic Index</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The secondary endpoint is defined as the treatment group difference in the change in insulinogenic index (baseline minus 3-month). This index is thought to reflect insulin secretion, and is derived from fasting and 30 min-post oral glucose tolerance testing glucose and insulin values. Insulinogenic index = [fasting insulin - insulin at time 30 min] / [fasting glucose - glucose at time 30 min]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to 3 Month Change in Composite of Insulin Resistance and Sensitivity, as Measured by the Oral Disposition Index</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The secondary endpoint is defined as the treatment group difference in the change in oral disposition index (baseline minus 3-month). This is thought to reflect a composite of both insulin resistance and secretion. Oral disposition index = insulinogenic index / fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline to 3-month Change in Matsuda Disposition Index</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change in disposition index from baseline to 3 months. This index is a composite measure thought to reflect insulin resistance and secretion. Matsuda disposition index = [Matsuda sensitivity index * insulinogenic index]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Insulin Resistance</condition>
  <condition>Glucose Intolerance</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet taken by mouth once a day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>20 mg Tadalafil taken once a day for 3 months</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Adcirca, Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet taken by mouth once a day for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and &lt; 50 years

          -  BMI &gt; 30 kg/m2

          -  Fasting insulin &gt; 10 uU/mL

        Exclusion Criteria:

          -  Systolic blood pressure (SBP) &lt; 100, &gt; 150 mmHg

          -  Current anti-hypertensive medication use, including diuretics

          -  Current use of organic nitrates

          -  Current use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil)

          -  History of reaction to PDE-5 inhibitors

          -  Known HIV infection

          -  Use of medications that strongly alter CYP3A4 activity

          -  History of myocardial infarction, angina, uncontrolled cardiac arrhythmia, stroke,
             transient ischemic attack, or seizure

          -  Known non-arteritic ischemic optic retinopathy (NAIOR)

          -  History of hearing loss

          -  Estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m2 by the modified diet
             in renal disease (MDRD) equation

          -  Hepatic transaminase (AST and ALT) levels greater than three times the upper limit of
             normal

          -  Known pregnancy or those unwilling to avoid pregnancy during the course of the study

          -  History of priapism

          -  Use in excess of four alcoholic drinks daily

          -  History of diabetes mellitus or use of anti-diabetic medications

          -  Known anemia (men, Hct &lt; 38% and women, Hct &lt; 36%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <results_first_submitted>July 11, 2016</results_first_submitted>
  <results_first_submitted_qc>December 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2017</results_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thomas J. Wang, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Tadalafil</keyword>
  <keyword>Phosphodiesterase 5 Inhibitors</keyword>
  <keyword>Cyclic Guanylyl Monophosphate Pathway</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Vasodilator Agents</keyword>
  <keyword>Cardiovascular Agents</keyword>
  <keyword>Obesity</keyword>
  <keyword>Glycemic Traits</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Glucose Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>111 participants screened, 38 excluded (34 did not meet eligibility criteria, 2 unable to obtain intravenous access, 2 withdrew consent)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil</title>
          <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-fasting</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil</title>
          <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="9"/>
                    <measurement group_id="B2" value="34" spread="9"/>
                    <measurement group_id="B3" value="33" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="6.8"/>
                    <measurement group_id="B2" value="36.8" spread="6.8"/>
                    <measurement group_id="B3" value="37.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting insulin</title>
          <units>microunits/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="10"/>
                    <measurement group_id="B2" value="17" spread="16"/>
                    <measurement group_id="B3" value="17" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR</title>
        <description>The primary endpoint is defined as the treatment group difference in the change in insulin resistance (baseline HOMA-IR minus 3-month HOMA-IR). HOMA-IR = [fasting glucose * fasting insulin]/405</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance From Baseline to 3 Months, as Measured by HOMA-IR</title>
          <description>The primary endpoint is defined as the treatment group difference in the change in insulin resistance (baseline HOMA-IR minus 3-month HOMA-IR). HOMA-IR = [fasting glucose * fasting insulin]/405</description>
          <units>mg*microunits/dL*mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="2.86"/>
                    <measurement group_id="O2" value="3.84" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81" spread="5.14"/>
                    <measurement group_id="O2" value="5.06" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear regression was used to model the change in HOMA-IR (3 month minus baseline value), comparing tadalafil versus placebo groups after adjusting for baseline HOMA-IR.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Linear</method>
            <param_type>beta estimate</param_type>
            <param_value>-1.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.29</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline to 3-month Change in Insulin Sensitivity, as Measured by the Matsuda Index</title>
        <description>The secondary endpoint is defined as the treatment group difference in the change in Matsuda Index (baseline minus 3-month). This index is a measure of insulin resistance derived from a frequently sampled oral glucose tolerance test, obtaining glucose and insulin levels in the fasting state, as well as 30, 60, 90, and 120 min after administration of oral glucose load. Matsuda index = 10,000/SQRT [fasting glucose*fasting insulin* (mean glucose from time 30, 60, 90, 120 min) * (mean insulin at time 30, 60, 90, and 120 min)]</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline to 3-month Change in Insulin Sensitivity, as Measured by the Matsuda Index</title>
          <description>The secondary endpoint is defined as the treatment group difference in the change in Matsuda Index (baseline minus 3-month). This index is a measure of insulin resistance derived from a frequently sampled oral glucose tolerance test, obtaining glucose and insulin levels in the fasting state, as well as 30, 60, 90, and 120 min after administration of oral glucose load. Matsuda index = 10,000/SQRT [fasting glucose*fasting insulin* (mean glucose from time 30, 60, 90, 120 min) * (mean insulin at time 30, 60, 90, and 120 min)]</description>
          <units>unitless index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="2.54"/>
                    <measurement group_id="O2" value="3.51" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="2.83"/>
                    <measurement group_id="O2" value="3.28" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear regression was used to model the change in Matsuda Index (3-month minus baseline), comparing tadalafil versus placebo groups after adjusting for baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Regression, Linear</method>
            <param_type>beta estimate</param_type>
            <param_value>0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline to 3-month Change in Endothelial Function Measured by EndoPAT</title>
        <description>Endothelial function was measured using the reactive hyperemia index, acquired using EndoPAT device. Peripheral arterial tonometry probes were placed on both index fingers. After a 5 min equilibration period, a blood pressure cuff was inflated to 200 mmHg and kept inflated for 5 min. The cuff was then rapidly deflated and the reactive hyperemic response pulse volume recorded, where RHI = ratio of hyperemic finger pulse volume (post-cuff inflation / pre-cuff inflation) to control finger pulse volume (post-cuff inflation / pre-cuff inflation)</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline to 3-month Change in Endothelial Function Measured by EndoPAT</title>
          <description>Endothelial function was measured using the reactive hyperemia index, acquired using EndoPAT device. Peripheral arterial tonometry probes were placed on both index fingers. After a 5 min equilibration period, a blood pressure cuff was inflated to 200 mmHg and kept inflated for 5 min. The cuff was then rapidly deflated and the reactive hyperemic response pulse volume recorded, where RHI = ratio of hyperemic finger pulse volume (post-cuff inflation / pre-cuff inflation) to control finger pulse volume (post-cuff inflation / pre-cuff inflation)</description>
          <units>unitless index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.7"/>
                    <measurement group_id="O2" value="2.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear regression was used to model the difference in EndoPAT (3-month minus baseline), comparing tadalafil to placebo groups after adjusting for baseline values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Regression, Linear</method>
            <param_type>beta estimate</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulinogenic Index</title>
        <description>The secondary endpoint is defined as the treatment group difference in the change in insulinogenic index (baseline minus 3-month). This index is thought to reflect insulin secretion, and is derived from fasting and 30 min-post oral glucose tolerance testing glucose and insulin values. Insulinogenic index = [fasting insulin - insulin at time 30 min] / [fasting glucose - glucose at time 30 min]</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Insulinogenic Index</title>
          <description>The secondary endpoint is defined as the treatment group difference in the change in insulinogenic index (baseline minus 3-month). This index is thought to reflect insulin secretion, and is derived from fasting and 30 min-post oral glucose tolerance testing glucose and insulin values. Insulinogenic index = [fasting insulin - insulin at time 30 min] / [fasting glucose - glucose at time 30 min]</description>
          <units>unitless index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="8.04"/>
                    <measurement group_id="O2" value="2.17" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="3.03"/>
                    <measurement group_id="O2" value="1.04" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear regression was used to model the change in insulinogenic index (3-month minus baseline), comparing tadalafil to placebo groups after adjusting for baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Regression, Linear</method>
            <param_type>beta estimate</param_type>
            <param_value>1.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline to 3 Month Change in Composite of Insulin Resistance and Sensitivity, as Measured by the Oral Disposition Index</title>
        <description>The secondary endpoint is defined as the treatment group difference in the change in oral disposition index (baseline minus 3-month). This is thought to reflect a composite of both insulin resistance and secretion. Oral disposition index = insulinogenic index / fasting insulin</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline to 3 Month Change in Composite of Insulin Resistance and Sensitivity, as Measured by the Oral Disposition Index</title>
          <description>The secondary endpoint is defined as the treatment group difference in the change in oral disposition index (baseline minus 3-month). This is thought to reflect a composite of both insulin resistance and secretion. Oral disposition index = insulinogenic index / fasting insulin</description>
          <units>unitless index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="11.56"/>
                    <measurement group_id="O2" value="2.87" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="4.62"/>
                    <measurement group_id="O2" value="0.58" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear regression was used to model the change in oral disposition index (3-month minus baseline), comparing tadalafil versus placebo groups after adjusting for baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Linear</method>
            <param_type>beta estimate</param_type>
            <param_value>3.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.38</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline to 3-month Change in Matsuda Disposition Index</title>
        <description>Change in disposition index from baseline to 3 months. This index is a composite measure thought to reflect insulin resistance and secretion. Matsuda disposition index = [Matsuda sensitivity index * insulinogenic index]</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline to 3-month Change in Matsuda Disposition Index</title>
          <description>Change in disposition index from baseline to 3 months. This index is a composite measure thought to reflect insulin resistance and secretion. Matsuda disposition index = [Matsuda sensitivity index * insulinogenic index]</description>
          <units>unitless index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="24.19"/>
                    <measurement group_id="O2" value="6.67" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.22" spread="8.51"/>
                    <measurement group_id="O2" value="0.19" spread="18.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear regression was used to model the change in Matsuda disposition index (3-month minus baseline), comparing tadalafil to placebo groups after adjusting for baseline value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Linear</method>
            <param_type>beta estimate</param_type>
            <param_value>8.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events recorded during study duration (3 months)</time_frame>
      <desc>Adverse events ascertained at each follow-up visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil</title>
          <description>20 mg Tadalafil tablet taken by mouth once a day for 3 months
Tadalafil: 20 mg Tadalafil taken once a day for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablet taken by mouth once a day for 3 months
Placebo: Placebo tablet taken by mouth once a day for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back or leg pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache and back ache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>arm pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Blurry vision and headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Ho</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6411</phone>
      <email>jho1@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

